secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0001628280-24-051956
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Aquestive 7-year orphan drug exclusivity for Libervant in pediatric seizure clusters ages 2-5
--------------------------------------------------------------------------------

- FDA granted 7 years of orphan drug exclusivity to Libervant (diazepam) Buccal Film for treating seizure clusters in patients aged 2-5.
- Exclusivity extends to April 2031; FDA cited buccal route as major contribution to patient care vs rectal route.
- Libervant is the first and only FDA-approved orally administered rescue therapy for this pediatric population.
- Originally designated as orphan drug in 2016; ODE now granted following approval on April 26, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024051956/0001628280-24-051956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024051956/aqst-20241219.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-051956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer